Corcept Therapeutics

The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. In addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. All of these compounds competitively block the glucocorticoid receptor (GR), but not the progesterone receptor. Scientific literature suggests that competitive GR antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, Alzheimer’s disease, alcoholism, prostate, breast and ovarian cancer, and weight gain caused by atypical anti-psychotic medications. We are investigating several of these indications in collaboration with researchers around the world.

Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
1998
Size (employees)
103 (est)
Corcept Therapeutics was founded in 1998 and is headquartered in Menlo Park, US

Corcept Therapeutics Office Locations

Corcept Therapeutics has an office in Menlo Park
Menlo Park, US (HQ)
149 Commonwealth Dr

Corcept Therapeutics Financials and Metrics

Corcept Therapeutics Financials

Corcept Therapeutics's revenue was reported to be $81.3 m in FY, 2016
USD

Net income (Q3, 2017)

13.8 b

EBIT (Q3, 2017)

13.6 b

Market capitalization (13-Dec-2017)

2.2 b

Cash (30-Sep-2017)

31.1 m
Corcept Therapeutics's current market capitalization is $2.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

10.4 m26.6 m50.3 m81.3 m

Revenue growth, %

156%89%62%

Cost of goods sold

143 k882 k1.4 m2.1 m

Gross profit

10.2 m25.7 m48.9 m79.3 m
USDQ2, 2017Q3, 2017

Cost of goods sold

775 m976 m

R&D expense

7.9 b11.7 b

General and administrative expense

14.1 b16.5 b

Operating expense total

22.8 b29.1 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

54.9 m24.2 m40.4 m51.5 m

Inventories

910 k1.4 m642 k2.3 m

Current Assets

58.3 m30.2 m49 m65.7 m

PP&E

203 k236 k98 k205 k
USDQ2, 2017Q3, 2017

Cash

33.6 m31.1 m

Inventories

3.1 m3.8 m

Current Assets

81.3 m93.9 m

PP&E

499 k553 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46 m)(31.4 m)(6.4 m)8.1 m

Inventories

(290 k)(531 k)799 k(682 k)

Accounts Payable

(1.4 m)(495 k)(561 k)965 k

Cash From Operating Activities

(37.1 m)(27.4 m)3.1 m18.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Accounts Receivable

1 m

Inventories

1 m1.1 m1.1 m1.1 m1.3 m1.5 m1.6 m1.9 m2.1 m2.3 m2.9 m

Accounts Payable

2.3 m3.7 m2.6 m2 m1 m2.4 m1.7 m2.1 m2.1 m4.3 m4.3 m
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

Corcept Therapeutics Market Value History

Corcept Therapeutics's Web-traffic and Trends

Corcept Therapeutics Online and Social Media Presence

Corcept Therapeutics Company Life and Culture

You may also be interested in